 |
市場調查報告書
商品編碼
1672653
冷凍乾燥藥物市場：依藥物類別、適應症、包裝類型、通路和地區分類Lyophilized Drugs Market, By Drug Class, By Indication, By Packaging Type, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
2025 年全球凍乾藥品市場規模預計為 3,710.9 億美元，預計到 2032 年將達到 6,831.8 億美元，2025 年至 2032 年的複合年成長率為 9.1%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 3710.90億美元 |
| 效能資料 | 從 2020 年到 2024 年 | 預測期 | 2025 至 2032 年 |
| 預測期：2025-2032年複合年成長率： | 9.10% | 2032 年價值預測 | 6831.8億美元 |
數字。 2025 年凍乾藥物市場佔有率（按地區分類）
全球冷凍乾燥藥物市場的成長得益於冷凍乾燥藥物的各種優勢，例如提高穩定性、易於管理和降低運輸成本。冷凍乾燥有助於去除製劑中的水分，防止微生物生長，從而延長藥品的保存期限。無需冷藏即可儲存和運輸藥品。由於慢性病的增加和製藥公司對新型藥物輸送解決方案的研發投入增加，預計預測期內對冷凍乾燥藥物的需求將大幅增加。
市場動態：
全球凍乾藥物市場的發展受到老年人口不斷成長、慢性病患病率上升以及凍乾藥物保存期限更長、微生物污染風險更低等優勢的推動。然而，預計冷凍乾燥設備和程序的高成本將抑制市場的成長。另一方面，由於醫療基礎設施的改善和醫療支出的增加，亞太和拉丁美洲的新興市場預計將為市場參與者提供豐厚的機會。此外，對新型、更高效的冷凍乾燥技術的持續研究和開發將在預測期內進一步為全球市場的擴張創造機會。
本研究的主要特點
- 本報告對全球凍乾藥物市場進行了詳細分析，並提供了預測期（2025-2032）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。
- 它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。
- 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
- 全球冷凍乾燥藥物市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行的分析。
- 本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
- 全球凍乾藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過用於分析全球凍乾藥物市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 限制因素
- 機會
- 影響分析
- 市場趨勢
- 主要進展
- 監管情景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
4. 全球冷凍乾燥藥物市場-冠狀病毒（COVID-19）大流行的影響
- 整體影響
- 政府舉措
- COVID-19 市場影響
5. 2020 年至 2032 年全球冷凍乾燥藥物市場（依藥品類別分類）（十億美元）
- 抗感染
- 抗癌藥物
- 利尿劑
- 質子幫浦抑制劑
- 麻醉劑
- 抗凝血劑
- NSAID
- 其他
6. 2020-2032 年全球冷凍乾燥藥物市場（按包裝類型分類）（十億美元）
- 管瓶
- 注射
- 墨水匣
7. 2020-2032 年全球凍乾藥物市場按分銷管道分類（十億美元）
- 醫院藥房
- 零售藥局
- 網路藥局
8. 2020 年至 2032 年全球冷凍乾燥藥物市場（依適應症分類）（十億美元）
- 腫瘤學
- 感染疾病
- 自體免疫疾病
- 消化系統疾病
- 皮膚病
- 呼吸系統疾病
- 眼科疾病
- 荷爾蒙失調
- 其他
9. 2020 年至 2032 年全球冷凍乾燥藥物市場（按地區分類）（十億美元）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 波灣合作理事會
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第10章 競爭格局
- 公司簡介
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- Johnson &Johnson
- Sanofi SA
- Amgen Inc.
- AbbVie Inc.
- Merck &Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan NV
- Celgene Corporation
- Novo Nordisk A/S
- Vertex Pharmaceuticals Incorporated
- Takeda Pharmaceutical Company Limited
第 11 章 分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第 12 章參考文獻與調查方法
- 參考
- 調查方法
簡介目錄
Product Code: CMI2930
Global Lyophilized Drugs Market is estimated to be valued at USD 371.09 Bn in 2025 and is expected to reach USD 683.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 371.09 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.10% | 2032 Value Projection: | USD 683.18 Bn |
Figure. Lyophilized Drugs Market Share (%), By Region 2025
The global lyophilized drugs market growth is driven by various advantages associated with lyophilization of drugs such as improved stability, ease of administration, and reduced transportation costs. Lyophilization or freeze-drying helps extend the shelf life of drugs by removing water from the formulations, thereby preventing the growth of microorganisms. It also enables storage and transportation of drugs without refrigeration. With the growing prevalence of chronic diseases and increasing R&D investments of pharmaceutical companies in novel drug delivery solutions, the demand for lyophilized drugs is expected to rise substantially during the forecast period.
Market Dynamics:
The global lyophilized drugs market is driven by the growing geriatric population, rising incidence of chronic diseases, and advantages of lyophilized drugs such as longer shelf life and lower risk of microbial contamination. However, high costs associated with lyophilization equipment and procedures are expected to restrain the market growth. On the other hand, emerging markets of Asia Pacific and Latin America are likely to offer lucrative opportunities for market players owing to improving healthcare infrastructure and increasing healthcare spending in these regions. Additionally, ongoing research for development of novel and more efficient lyophilization technologies will further create opportunities for the expansion of the global market during the forecast period.
Key Features of the Study:
- This report provides in-depth analysis of the global lyophilized drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global lyophilized drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Baxter International Inc., Jadavpur University, Merck & Co., Inc., and GlaxoSmithKline plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lyophilized drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lyophilized drugs market
Detailed Segmentation-
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Oncology
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Dermatological Disorders
- Respiratory Diseases
- Ophthalmic Diseases
- Hormonal Disorders
- Others
- By Packaging Type
- Vial
- Injection
- Cartridge
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- Johnson & Johnson
- Sanofi S.A.
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Celgene Corporation
- Novo Nordisk A/S
- Vertex Pharmaceuticals Incorporated
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Indication
- Market Snapshot, By Packaging Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Lyophilized Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Lyophilized Drugs Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Anti-infective
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antineoplastic
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diuretics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Proton Pump Inhibitor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anesthetic
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticoagulant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- NSAID's
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Lyophilized Drugs Market, By Packaging Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Vial
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injection
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cartridge
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Lyophilized Drugs Market, By Distribution Channel , 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Lyophilized Drugs Market, By Indication, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Autoimmune Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastrointestinal Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dermatological Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Respiratory Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ophthalmic Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hormonal Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Lyophilized Drugs Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel2019 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Roche Holding AG
- Johnson & Johnson
- Sanofi S.A.
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Celgene Corporation
- Novo Nordisk A/S
- Vertex Pharmaceuticals Incorporated
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
